



May 19, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : *Intimation regarding the divestment by HealthCare Global Enterprises Limited of its entire equity shareholding in BACC Health Care Private Limited to Inviga Healthcare Fund I*

Stock Code : *BSE – 539787, NSE – HCG*

Reference : *Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026 (“SEBI Circular”)*

We would like to inform you that the Board of Directors of the Company has, at their meeting held today, i.e., May 19, 2026, approved the divestment by way of sale of HealthCare Global Enterprises Limited’s (“*the Company*”) entire equity shareholding in BACC Health Care Private Limited (“*BACC*”) to Inviga Healthcare Fund I and its nominee (“*Buyer*”), for a consideration of INR 37,64,44,788 (Indian Rupees Thirty Seven Crores Sixty Four Lakhs Forty Four Thousand Seven Hundred and Eighty Eight Only), on the terms agreed under a Share Purchase Agreement (“*SPA*”) to be entered into amongst the Company, BACC and the Buyer (the “*Proposed Transaction*”). BACC is not a material subsidiary of the Company and is engaged in the business of fertility and reproductive healthcare services, which is not a core business activity of the Company.

The Proposed Transaction is a related party transaction and has been approved by the Audit Committee and the Board of Directors of the Company. The Proposed Transaction was finalised following a competitive process and is being undertaken on an arm’s length basis. The consideration for the Proposed Transactions takes into account the valuation report by an independent third-party valuer.

The Proposed Transaction is aligned with the Company’s broader strategic and capital allocation objectives and is expected to facilitate greater operational focus and business alignment, allowing the Company to reinvest capital in high growth areas and cancer services.

The Board meeting commenced at 11.30 a.m. IST and concluded at 10.30 p.m. IST.

HealthCare Global Enterprises Limited

Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027, Karnataka, India
Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India
91 80 4660 7700 | Email-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489

Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag



Detailed information in this regard in accordance with Regulation 30 read with SEBI Circulars SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, is annexed herewith as **Annexure-A**.

The above information is also available on the website of the Company and can be accessed at: <https://www.hcgoncology.com/>

You are requested to take the information on record.

Thanking You,

For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary and Compliance Officer.
Encl: a/a



ANNEXURE – A

Disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para 1.4 of Part A of Annexure 18 of the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026.

Sr. No.	Particulars	Details		
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year.	Revenue from operations and net worth of BACC Health Care Private Limited (“BACC”) during the financial year 2025-26:		
		Particulars	Amount (INR; in Crores)	Percentage of BACC’s revenue and net worth as a % of HCG Standalone revenue from operations and net worth respectively, for the period/year ended March 31, 2026
		Revenue From Operations of BACC for FY 25-26	60.45	4.45%
		Net worth of BACC as at March 31, 2026	17.53	1.09%
		Above figures and percentage are based on the financial statements of BACC and HCG standalone for FY 2025-26		
		Net worth shall mean Total Assets minus Total Liabilities		
2.	Date on which the agreement for sale has been entered into;	The Company proposes to execute the SPA on May 19, 2026.		
3.	The expected date of completion of sale/disposal;	The completion of the Proposed Transaction is expected to occur within 4-5 weeks from the date hereof, subject to the terms of the SPA.		



4.	Consideration received from such sale/disposal;	<p>The Company is expected to receive an amount of INR 37,64,44,788 (Indian Rupees Thirty-Seven Crores Sixty-Four Lakhs Forty-Four Thousand Seven Hundred and Eighty-Eight Only) (subject to agreed deductions / adjustments under the SPA), in the following tranches:</p> <p>(a) an aggregate consideration of INR 28,23,33,591 (Indian Rupees Twenty-Eight Crores Twenty-Three Lakhs Thirty-Three Thousand Five Hundred and Ninety-One Only), on the date of closing; and</p> <p>(b) aggregate deferred consideration of INR 9,41,11,197 (Indian Rupees Nine Crores Forty-One Lakhs Eleven Thousand One Hundred and Ninety-Seven Only) within 18 (eighteen) months of the date of signing of the SPA.</p> <p>The deferred consideration referenced above is not a conditional or contingent payment.</p>
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	<p>The Buyer is Inviga Healthcare Fund I and its nominee.</p> <p>Dr. B.S. Ajaikumar, Promoter and Non-Executive Chairman of the Board of the Company is the Sponsor of the Inviga Healthcare Fund I (“Fund”) and also the Promoter of Inviga Investment Advisors Private Limited, the Investment Manager of the Fund. Accordingly, the Fund is controlled by Dr. B S Ajaikumar.</p>
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	<p>Yes, the Proposed Transaction would fall within a related party transaction and is being undertaken on an arm’s length basis.</p> <p>The consideration for the Proposed Transaction was based on, inter alia, a valuation report by an independent third-party valuer.</p> <p>The Company undertook a competitive process in relation to the Proposed Transaction.</p>
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Not Applicable.
8.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable.